Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924094 | 0.89 | ALOX5AP (0.41) | APPACACBALOX5LMNAPOLB | |
| SCHEMBL3000188 | 0.85 | ACACB (0.46) | ACACBALOX5RAB9AALOX5AP | |
| SCHEMBL2993269 | 0.83 | NR4A2 (0.49) | ACACBPOLBRAB9A | |
| SCHEMBL2989839 | 0.82 | ACACB (0.48) | ACACBLMNAPOLBRAB9A | |
| SCHEMBL2995588 | 0.79 | APP (0.49) | APPLMNAPOLBRAB9AATM | |
| SCHEMBL3000902 | 0.79 | ALOX5AP (0.43) | ACACBALOX5LMNAPOLBRAB9A | |
| SCHEMBL2995628 | 0.78 | NPC1 (0.46) | ACACBRAB9AL3MBTL1ALOX5AP | |
| Ammonia Solution, Strong SCHEMBL2997486 | 0.78 | ACACB (0.37) | ACACBALOX5ALOX5APMMP9MMP13 | |
| SCHEMBL14396684 | 0.78 | ALOX5AP (0.41) | ACACBLMNAPOLBRAB9AALOX5AP | |
| SCHEMBL2798446 | 0.78 | ACACB (0.42) | ACACBALOX5LMNAPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | APP 722/4885ACACB 1284/4885ALOX5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.